The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Open accessAbstract
Background: Omicron subvariant BA.2 circulation is rapidly increasing globally. Aim: We evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants. Methods: Using 50% plaque reduction neutralisation tests (PRNT 50), we assessed neutralising antibody titres to BA.2, wild type (WT) SARS-CoV-2 and other variants in Comirnaty or CoronaVac vaccinees, with or without prior WT-SARS-CoV-2 infection. Titres were also measured for non-vaccinees convalescing from a WT-SARS-CoV-2 infection. Neutralising antibodies in BA.2 and BA.1 breakthrough infections and in BA.2 infections affecting non-vaccinees were additionally studied. Results: In vaccinees or prior WT-SARS-CoV-2-infected people, BA.2 and BA.1 PRNT 50 titres were comparable but significantly (p < 10 − 5) lower than WT. In each group of 20 vaccinees with (i) three-doses of Comirnaty, (ii) two CoronaVac followed by one Comirnaty dose, or (iii) one dose of either vaccine after a WT-SARS-CoV-2 infection, ≥ 19 individuals developed detectable (PRNT 50 titre ≥ 10) antibodies to BA.2, while only 15 of 20 vaccinated with three doses of CoronaVac did. Comirnaty vaccination elicited higher titres to BA.2 than CoronaVac. In people convalescing from a WT-SARS-CoV-2 infection, a single vaccine dose induced higher BA.2 titres than three Comirnaty (p = 0.02) or CoronaVac (p = 0.00001) doses in infection-naïve individuals. BA.2 infections in previously uninfected and unvaccinated individuals elicited low (PRNT 50 titre ≤ 80) responses with little cross-neutralisation of other variants. However, vaccinees with BA.1 or BA.2 breakthrough infections had broad cross-neutralising antibodies to WT viruses, and BA.1, BA.2, Beta and Delta variants. Conclusions: Existing vaccines can be of help against the BA.2 subvariant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The estimated VE against BA.2 infection elicited by three doses of CoronaVac appears greater than would be expected from neutralizing antibody titers.
“Thus, our estimate of VE against BA.2 infection elicited by three doses of CoronaVac appears greater than would be expected from neutralizing antibody titers.”
From Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,381
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04594-4 · Cited by 785
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01700-x · Cited by 409
Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Malik, A. A., De la Cruz, E., Jorge, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01705-6 · Cited by 401
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Swadling, L., Diniz, M. O., Schmidt, N. M., Amin, O. E., Chandran, A., Shaw, E., Pade, C., Gibbons, J. M., Bert, N. L., Tan, A. T., et al. (2021) · Nature · doi:10.1038/s41586-021-04186-8 · Cited by 395
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00345-0 · Cited by 360
Cheng, S. M. S., Mok, C. K. P., Leung, Y. W. Y., Ng, S. S., Chan, K., Ko, F. W. S., Chen, C., Yiu, K. K. L., Lam, B. H., Lau, E. H. Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01704-7 · Cited by 356
Self-citationZeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 319
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Liu, Y., Soh, W. T., Kishikawa, J.-I., Hirose, M., Nakayama, E. E., Li, S., Sasai, M., Suzuki, T., Tada, A., Arakawa, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.032 · Cited by 274
SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Pilz, S., Theiler‐Schwetz, V., Trummer, C., Krause, R. G. E., & Ioannidis, J. P. A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112911 · Cited by 273
Wratil, P. R., Stern, M., Priller, A., Willmann, A., Almanzar, G., Vogel, E., Feuerherd, M., Cheng, C., Yazici, S., Christa, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01715-4 · Cited by 240
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K., Yiu, K., Chan, T., Bull, M., Ling, K. C., Dai, Z., et al. (2022) · Respirology · doi:10.1111/resp.14191 · Cited by 162
Self-citationSARS-CoV-2 Omicron VOC Transmission in Danish HouseholdsPreprint
Lyngse, F. P., Mortensen, L. H., Denwood, M. J., et al. (2021) · medRxiv · doi:10.1101/2021.12.27.21268278 · Cited by 157
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153
Emergence of Omicron third lineage BA.3 and its importance
Desingu, P. A., Nagarajan, K., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27601 · Cited by 144
How COVID vaccines shaped 2021 in eight powerful charts
Mallapaty, S., Callaway, E., Kozlov, M., et al. (2021) · Nature · doi:10.1038/d41586-021-03686-x · Cited by 121
Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 109
Lau, E. H. Y., Hui, D. S. C., Tsang, O. T., Chan, W. H., Kwan, M. Y. W., Chiu, S. S. S., Cheng, S. M. S., Ko, R. L., Li, J. K., Chaothai, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101174 · Cited by 71
Self-citationOmicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variantsPreprint
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F. D., Bestebroer, T. M., de Wit, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.23.481644 · Cited by 43
Mok, C. K. P., Chen, C., Chen, C., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202111-2655le · Cited by 39
Self-citationDoes the world need an Omicron vaccine? What researchers say
Waltz, E. (2022) · Nature · doi:10.1038/d41586-022-00199-z · Cited by 20
Flagged first, then by citations
Research works printed but not linked: 2
- Yamasoba, 2022, Virological characteristics of SARS-CoV-2 BA.2 variant., bioRxiv
- McMenamin, Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong., medRxiv
Cited by
Sorted by citations
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02219-5 · Cited by 198
Self-citation
Metadata
- Authors
- Cheng, S. M., Mok, C. K. P., Chan, K. C., Ng, S. S., Lam, B. H., Luk, L. L., Ko, F. W., Chen, C., Yiu, K., Li, J. K., Chan, K. K., Tsang, L. C., Poon, L. L., Hui, D. S., & Peiris, M.
- Affiliations
- University of Hong Kong (HK)
- Chinese University of Hong Kong (HK)
- School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Department of Pathology, North Lantau Hospital, Hong Kong SAR, China
- Hong Kong Science and Technology Parks Corporation (HK)
- ORCID
- Venue
- Eurosurveillance
- Published
- 2022-05-05
- Volume
- 27
- Issue
- 18
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- PMC
- PMC9074393
- OpenAlex
- W4229008155
- Cited by
- 31
- References
- 27
- Citations by year
- 2024: 4 · 2023: 8 · 2022: 19
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Eurosurveillance (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Nanyang Technological University
- National Natural Science Foundation of China (COVID-19, N_HKU737/18)
- Innovation and Technology Commission
- National Institutes of Health (COVID-19)
- Health and Medical Research Fund (T11-705/21-N, COVID190126, COVID1903003)
- Lee Kong Chian School of Medicine, Nanyang Technological University
- National Institute of Allergy and Infectious Diseases (U01AI151810)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- neutralizing antibodies, BNT162b2, CoronaVac, COVID-19 vaccination, breakthrough infection, prior SARS-CoV-2 infection, cross-neutralization, vaccine efficacy, Hong Kong
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Antibodies, Viral, Hong Kong, Humans, Vaccination, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
